NCPC has obtained the drug registration certificate for injectable isavuconazole
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, NCPC announced that the company recently received the "Drug Registration Certificate" for injectable isavuconazole (0.2g) approved by the National Medical Products Administration. The indications for this drug are the same as those approved in the United States and the European Union, used for the treatment of invasive aspergillosis and mucormycosis in adults, with the brand name Cresemba
According to the Zhitong Finance APP, NCPC (600812.SH) announced that the company recently received the "Drug Registration Certificate" for injectable isavuconazole (0.2g) approved by the National Medical Products Administration.
The indications for this drug are the same as those approved in the United States and the European Union, used for the treatment of adult invasive aspergillosis and mucormycosis, with the brand name Cresemba